Nasser Altorki, MD, Jonathan D. Spicer, MD, PhD, FRCSC - Realizing the Promise of Perioperative Immunotherapy in Resectable NSCLC: How to Modernize Best Practices Based on New Evidence and Better Multidisciplinary Alliances

PeerView Clinical Pharmacology CME/CNE/CPE Video

Go online to PeerView.com/YRK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The immunotherapy revolution has swiftly expanded from advanced lung cancer to the early-stage, resectable, curative-intent setting, and it is radically transforming the standards of care for stage I-III resectable NSCLC. Immunotherapies are now approved in both adjuvant and neoadjuvant settings, and ongoing trials are expected to propel more immunotherapy-based options into early-stage disease settings as well as clarify the best perioperative approaches. What do these developments mean for thoracic surgeons and other members of the multidisciplinary lung cancer care team? How should best practices and standards of care be modernized? What new workflows need to be established to guide individualized treatment selection and make the most of new immunotherapy options to reduce the risk of recurrence and increase the possibility of cure for more patients? This PeerView educational activity, based on a recent live symposium, brings together top experts to answer these questions. The faculty panel discusses new, practice-changing evidence, implications and applicability of these advances to practice, and how to best facilitate the incorporation of perioperative immunotherapy into new standards of care to improve outcomes and quality of life for patients with resectable NSCLC. Upon completion of this activity, participants should be better able to: Analyze the current evidence supporting the use of neoadjuvant and adjuvant immunotherapy approaches in stage I-III NSCLC, including the biologic and mechanistic rationale, novel endpoints, and data from key clinical trials; Identify patients with resectable NSCLC who are candidates for perioperative immunotherapy; and Implement neoadjuvant and/or adjuvant immunotherapy as part of individualized treatment plans for patients with resectable stage I-III NSCLC based on all the relevant factors, effective multidisciplinary collaboration, and shared decision-making